April 2023 in “European urology open science” Urologists should screen for mental health issues before and during finasteride treatment.
March 2023 in “The Journal of Urology” Higher SRD5A2 expression predicts better response to finasteride in treating urinary symptoms.
September 2022 in “Dermatology and therapy” Androgenetic alopecia is linked to heart disease, metabolic issues, and mental health problems.
May 2022 in “Current Enzyme Inhibition” Compound 7b is a promising candidate for treating benign prostatic hyperplasia and prostate cancer.
May 2022 in “The Journal of Sexual Medicine” Finasteride is linked to sexual dysfunction, especially in younger men using it for hair loss.
April 2022 in “The Journal of Sexual Medicine” Finasteride alone increases suicide risk, but combining it with other treatments reduces this risk.
April 2022 in “The Journal of Sexual Medicine” Finasteride is linked to sexual dysfunction, especially in younger users treating hair loss.
November 2021 in “Evidencia” Young patients using finasteride may have higher risks of anxiety, depression, and suicidal thoughts.
August 2021 in “The Journal of Urology” Finasteride use is strongly linked to sexual dysfunction, especially in young men treating hair loss.
May 2021 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Clinicians need to better understand and treat Post-finasteride syndrome.
July 2020 in “Vestnik urologii” The cause of post-finasteride syndrome is unclear and needs more research.
January 2020 in “Archives of urology” Finasteride, a drug used for certain conditions, can cause serious side effects like sexual dysfunction, suicidal thoughts, and increased diabetes risk, and there's a need for more awareness and research about these effects.
Finasteride use is linked to a higher risk of obstructive sleep apnea.
December 2019 in “Reactions Weekly” Man stopped medications due to sexual side effects, found relief with prostatic artery embolisation.
August 2018 in “Daehan binyogi jong-yang haksulji” Taking sildenafil and finasteride together is safe and improves urinary and sexual symptoms in BPH patients.
January 2018 in “International Journal of Medical Research and Health Sciences” Finasteride reduces blood loss and the need for blood transfusions during and after TURP surgery.
August 2017 in “Drug and Therapeutics Bulletin” Finasteride may cause depression, suicidal thoughts, and sexual side effects.
July 2017 in “Reactions Weekly” Finasteride may cause serious muscle-related side effects.
April 2017 in “The Journal of Urology” Finasteride before TURP reduces blood loss and improves early postoperative quality of life.
December 2016 in “Reactions Weekly” Dutasteride and finasteride have equal safety for treating BPH without increased heart risk.
September 2016 in “Reactions Weekly” Dutasteride and finasteride don't raise erectile dysfunction risk.
March 2016 in “European Urology Supplements” Methylation in specific gene region causes finasteride resistance in some BPH patients.
January 2016 in “Reactions Weekly” No clear link found between finasteride and suicidal thoughts or actions.
December 2015 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Finasteride, a hair loss treatment, may cause long-term sexual dysfunction and depression.
October 2015 in “Elsevier eBooks” Finasteride helps hair growth and prostate issues but may cause sexual side effects and increase tumor risk.
January 2015 in “프로그램북(구 초록집)” Dutasteride is effective and safe for treating common hair loss, and it's more potent than finasteride, leading to better hair growth and thickness.
January 2014 in “프로그램북(구 초록집)” 5AR inhibitors like finasteride and dutasteride improve hair growth and slow hair loss in male pattern baldness.
February 2010 in “Journal of The American Academy of Dermatology” Lower nitric oxide and higher fibrinogen found in hirsute women; impaired sexual function in 22.6% of hair loss patients, linked to psoriasis severity.
September 2005 in “Archives of Dermatological Research” Large prostate patients more likely to have hair loss.
37 citations
,
September 2008 in “The American journal of surgical pathology” Hair follicle hyperplasia is common in both benign and malignant skin lymphoproliferative disorders, with a proposed new term "pseudolymphomatous adnexitis."